Laboratoire français de Fractionnement et de Biotechnologies
As of the edition of 20 October 2026, Laboratoire français de Fractionnement et de Biotechnologies runs 3 drugs; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 3 |
| Total | 3 |
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Laboratoire français de Fractionnement et de Biotechnologies needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 3 trials led
- Nervous system: 2 trials led
- Blood and lymph: 1 trials led